Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
T-Wave Alternans test · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| T-Wave Alternans test | DEVICE | - |
Inclusion Criteria: Patients with no previous history of life threatening ventricular arrhythmias or symptomatic non-sustained VT, and who meet the following inclusion criteria may be enrolled in the study: 1. Ischemic heart disease as documented by any of the following: previous myocardial infarc...
The T-Wave Alternans test is a diagnostic tool used in patients with Ischemic Cardiomyopathy and left ventricular dysfunction to assess their risk for life-threatening heart rhythms. It is being studied as an alternative to the EPS test for predicting which patients are at risk for dangerous arrhythmias.
The T-Wave Alternans test is developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. Abbott is conducting clinical research to evaluate the test's ability to predict life-threatening heart rhythms in patients with ischemic cardiomyopathy.
The T-Wave Alternans test is in Phase 3 clinical development. It is an investigational diagnostic test, not yet approved by the FDA. The Phase 3 study, known as the ABCD Study, has been completed and enrolled 618 participants with ischemic cardiomyopathy and left ventricular dysfunction.
The T-Wave Alternans test has one completed Phase 3 clinical trial, registered as NCT00187291. This study, titled 'Study to Compare TWA Test and EPS Test for Predicting Patients at Risk for Life-threatening Heart Rhythms (ABCD Study)', enrolled 618 participants with ischemic cardiomyopathy and left ventricular dysfunction.
No, the T-Wave Alternans test is not the same as the EPS test. The T-Wave Alternans test is a non-invasive diagnostic method being studied as a potential alternative to the EPS test. The ABCD Study was designed to compare the two tests for predicting life-threatening heart rhythms in patients with ischemic cardiomyopathy.